A comprehensive literature analysis has evaluated the cost-effectiveness of using nirmatrelvir/ritonavir as a treatment for COVID-19. The study reviewed multiple healthcare economic models and found that administering the antiviral therapy, particularly in high-risk patient groups, led to reduced hospitalization rates and lower overall medical expenditures. Despite its initial high price, the intervention demonstrated long-term savings by preventing severe disease progression. Researchers emphasized the importance of timely access to the drug in controlling both health and economic burdens during pandemic waves.
— news from Taylor & Francis Online
— News Original —
Just a moment…
Full article: Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review Taylor & Francis Online